Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27192956 | 0.91 | SMN1; SMN2 (0.35) | SMN1; SMN2LMNATHRBHIF1AKMT2A | |
| SCHEMBL29637594 | 0.91 | LMNA (0.39) | SMN1; SMN2LMNATHRBHIF1AALDH1A1 | |
| SCHEMBL24547495 | 0.89 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNATHRBHIF1AKMT2A | |
| SCHEMBL27192937 | 0.88 | SMN1; SMN2 (0.34) | SMN1; SMN2LMNATHRBHIF1AKMT2A | |
| SCHEMBL27192952 | 0.86 | SMN1; SMN2 (0.34) | SMN1; SMN2LMNATHRBHIF1AKMT2A | |
| SCHEMBL27192946 | 0.85 | DEGS1 (0.35) | SMN1; SMN2LMNATHRBHIF1APOLB | |
| SCHEMBL27192960 | 0.85 | LMNA (0.32) | SMN1; SMN2LMNATHRBHIF1A | |
| SCHEMBL27192942 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNATHRBHIF1APOLB | |
| SCHEMBL24547494 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNATHRBHIF1APOLB | |
| SCHEMBL27192955 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNATHRBHIF1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116972-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RES INST (US) | 2024-04-11 | — | — | US | disclosed |
| US-11858956-B2 | 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections | SOUTHERN RESEARCH INSTITUTE (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220204545-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2022-06-30 | — | — | US | disclosed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204545-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | MTAP, GALE, TPMT | SMN1; SMN2 331/4885LMNA 2431/4885THRB 4455/4885 |
| US-20240116972-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | MTAP, GALE, TPMT | SMN1; SMN2 331/4885LMNA 2431/4885THRB 4455/4885 |
| US-11858956-B2 | 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections | MTAP, GALE, TPMT | SMN1; SMN2 331/4885LMNA 2431/4885THRB 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.